(“NetScientific” or the “Group”)
Capital Markets Day
London, UK – 29 April 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, will be holding a Capital Markets Day on Friday 15 May 2015 at 10.30am – 3.00pm in London to provide an update on the outcome of its strategy review and highlight the achievements and progress of its key portfolio companies.
Sir Richard Sykes will introduce the day and provide a strategy update, then seven key portfolio companies will present. This will be followed by an opportunity to network and meet the portfolio companies on a one to one basis.
Attending portfolio companies include (full details of the companies are below):
· Wanda Health
· G-Tech Medical
· Vortex BioSciences
· PDS Biotechnology
Please email email@example.com for more details or to book a one to one meeting.
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net.
Attending portfolio companies
Wanda Health – Healthcare Analytics
· Wanda Health is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA. Wanda Health completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure, the leading cause of hospital re-admissions in USA.
Glucosense – Wearables
· Glucosense is developing a non-invasive blood glucose sensor, which has a number of potential professional and consumer applications. These include as a partial replacement for the finger-prick testing, continuous non-invasive glucose monitoring and as a wearable hypoglycaemia-alert device.
G-Tech Medical – Wearables
· G-Tech Medical is developing a wireless, wearable, disposable patch, which will help diagnose the root causes of Functional Gastrointestinal Disorders (‘FGIDs’). FGIDs afflict more than 60 million people annually in the US, and are a large burden to the health care system. The G-Tech patch will measure and characterize the activity of the main digestive organs under normal daily conditions to help pinpoint the source of the dysfunction. It will allow physicians to quickly determine that a functional problem exists, in many cases allowing them to skip the current invasive, expensive anatomic testing sequence.
Vortex Biosciences – Cancer diagnostic
· Cancer diagnostic instrument company providing liquid biopsy solutions for isolating, detecting and harvesting circulating tumour cells (‘CTCs’) from cancer patients’ blood samples. The company is developing the Vortex VX-1 benchtop instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers. The instrument harvests live CTCs from patient blood samples for use in downstream clinical applications such as monitoring disease progression and drug treatment effectiveness.
Glycotest – Liver diagnostics
· Glycotest is developing diagnostic tests designed to support the accurate diagnosis of liver disease, liver cancers and fibrosis-cirrhosis, and ultimately help improve disease management in patients. The technology was spun-out of the Drexel University College of Medicine and the Baruch S. Blumberg Institute. The first diagnostic panel under development, measures serum levels of multiple liver proteins using the company’s proprietary technology to detect early stage Hepatocellular Carcinoma (‘HCC’), improving surveillance of the disease in high-risk populations.
ProAxsis – Respiratory diagnostics
· The company is developing a range of novel, point of care, easy to use tests, which will enable routine monitoring and improved management of patients with chronic conditions, such as cystic fibrosis and chronic obstructive pulmonary disease. The lead product, NEATstickTM, detects active neutrophil elastase, which is an early indicator of lung infection in patients with cystic fibrosis. In parallel with this, ProAxsis is also developing a range of activity-base immunoassays, which will assist the research community in the specific measurement of activated protease disease-biomarkers. Later in 2015, the launch of the first ProteaseTagsTM immunoassay tests is anticipated as well as the completion of pre-clinical development of NEATstickTM.
PDS Biotechnology – Cancer immunotherapy
· PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. Versamune®, its novel synthetic nanoparticle platform technology, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system. The company’s lead product, PDS0101, is in phase I clinical trials in the US for HPV-related cancers. PDS has licensed the Versamune® technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company has also ongoing pre-clinical programmes for other cancers as well as pandemic influenza.
Peter Thoms, CFO
Tel: +44 (0)77 2055 5752
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7597 4000
Melanie Toyne-Sewell / Jayne Crook
Tel: +44 (0)20 7457 2020 Email: firstname.lastname@example.org